Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1979 Aug;76(8):4097–4101. doi: 10.1073/pnas.76.8.4097

13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor.

G C Le Breton, D L Venton, S E Enke, P V Halushka
PMCID: PMC383985  PMID: 291066

Abstract

A newly synthesized 13-aza derivative of prostanoic acid (13-APA) specifically inhibited human platelet aggregation induced by arachidonic acid, prostaglandin H2, or the stable endoperoxide analog (15S)-hydroxy-9 alpha,11 alpha-)epoxymethano)-prosta-5Z,13E-dienoic acid. 13-APA also inhibited [14C]serotonin release in response to arachidonic acid, ADP, or thrombin, but did not inhibit primary aggregation induced by ADP or thrombin. 13-APA completely blocked prostaglandin H2-induced aggregation in indomethacin-treated resuspended platelets but did not inhibit thromboxane synthesis. We therefore conclude that 13-APA acts as a direct antagonist of the platelet thromboxane/endoperoxide receptor.

Full text

PDF
4097

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander R. W., Kent K. M., Pisano J. J., Keiser H. R., Cooper T. Regulation of postocclusive hyperemia by endogenously synthesized prostaglandins in the dog heart. J Clin Invest. 1975 Jun;55(6):1174–1181. doi: 10.1172/JCI108034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alusy U. D., Hammarström S. Inhibitors of thromboxane synthase in human platelets. FEBS Lett. 1977 Oct 1;82(1):107–110. doi: 10.1016/0014-5793(77)80896-x. [DOI] [PubMed] [Google Scholar]
  3. BORN G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962 Jun 9;194:927–929. doi: 10.1038/194927b0. [DOI] [PubMed] [Google Scholar]
  4. BORN G. V. STRONG INHIBITION BY 2-CHLOROADENOSINE OF THE AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE. Nature. 1964 Apr 4;202:95–96. doi: 10.1038/202095b0. [DOI] [PubMed] [Google Scholar]
  5. Ball G., Brereton G. G., Fulwood M., Ireland D. M., Yates P. Effet of prostaglandin E1 alone and in combination with theophylline or aspirin on collagen-induced platelet aggregation and on platelet nucleotides including adenosine 3':5'-cyclic monophosphate. Biochem J. 1970 Dec;120(4):709–718. doi: 10.1042/bj1200709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bergström S. Prostaglandins: members of a new hormonal system. These physiologically very potent compounds of ubiquitous occurrence are formed from essential fatty acids. Science. 1967 Jul 28;157(3787):382–391. doi: 10.1126/science.157.3787.382. [DOI] [PubMed] [Google Scholar]
  7. Best L. C., Martin T. J., Russell R. G., Preston F. E. Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets. Nature. 1977 Jun 30;267(5614):850–852. doi: 10.1038/267850a0. [DOI] [PubMed] [Google Scholar]
  8. Bills T. K., Smith J. B., Silver M. J. Metabolism of [14C]arachidonic acid by human platelets. Biochim Biophys Acta. 1976 Feb 23;424(2):303–314. doi: 10.1016/0005-2760(76)90198-3. [DOI] [PubMed] [Google Scholar]
  9. Blackwell G. J., Duncombe W. G., Flower R. J., Parsons M. F., Vane J. R. The distribution and metabolism of arachidonic acid in rabbit platelets during aggregation and its modification by drugs. Br J Pharmacol. 1977 Feb;59(2):353–366. doi: 10.1111/j.1476-5381.1977.tb07500.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Castaldi P. A. Prophylactic agents for thrombosis. Drugs. 1975;9(1):1–3. doi: 10.2165/00003495-197509010-00001. [DOI] [PubMed] [Google Scholar]
  11. Emmons P. R., Hampton J. R., Harrison M. J., Honour A. J., Mitchell J. R. Effect of prostaglandin E1 on platelet behaviour in vitro and in vivo. Br Med J. 1967 May 20;2(5550):468–472. doi: 10.1136/bmj.2.5550.468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Feinstein M. B., Becker E. L., Fraser C. Thrombin, collagen and A23187 stimulated endogenous platelet arachidonate metabolism: differential inhibition by PGE1, local anesthetics and a serine-protease inhibitor. Prostaglandins. 1977;14(6):1075–1093. doi: 10.1016/0090-6980(77)90286-6. [DOI] [PubMed] [Google Scholar]
  13. Fields W. S., Lemak N. A., Frankowski R. F., Hardy R. J. Controlled trial of aspirin in cerebral ischemia. Stroke. 1977 May-Jun;8(3):301–314. doi: 10.1161/01.str.8.3.301. [DOI] [PubMed] [Google Scholar]
  14. Fitzpatrick F. A., Bundy G. L., Gorman R. R., Honohan T. 9,11-epoxyiminoprosta-5,13-dienoic acid is a thromboxane A2 antagonist in human platelets. Nature. 1978 Oct 26;275(5682):764–766. doi: 10.1038/275764a0. [DOI] [PubMed] [Google Scholar]
  15. Fitzpatrick F. A., Gorman R. R. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors. Biochim Biophys Acta. 1978 Mar 1;539(2):162–172. doi: 10.1016/0304-4165(78)90003-x. [DOI] [PubMed] [Google Scholar]
  16. Genton E., Gent M., Hirsh J., Harker L. A. Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (first of three parts). N Engl J Med. 1975 Dec 4;293(23):1174–1178. doi: 10.1056/NEJM197512042932305. [DOI] [PubMed] [Google Scholar]
  17. Gorman R. R., Bundy G. L., Peterson D. C., Sun F. F., Miller O. V., Fitzpatrick F. A. Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid. Proc Natl Acad Sci U S A. 1977 Sep;74(9):4007–4011. doi: 10.1073/pnas.74.9.4007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hamberg M., Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci U S A. 1974 Sep;71(9):3400–3404. doi: 10.1073/pnas.71.9.3400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hamberg M., Svensson J., Samuelsson B. Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proc Natl Acad Sci U S A. 1974 Oct;71(10):3824–3828. doi: 10.1073/pnas.71.10.3824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hamberg M., Svensson J., Wakabayashi T., Samuelsson B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci U S A. 1974 Feb;71(2):345–349. doi: 10.1073/pnas.71.2.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Haslam R. J., Lynham J. A. Activation and inhibition of blood platelet adenylate cyclase by adenosine or by 2-chloroadenosine. Life Sci II. 1972 Dec 8;11(23):1143–1154. doi: 10.1016/0024-3205(72)90269-x. [DOI] [PubMed] [Google Scholar]
  23. Haslam R. J., Rosson G. M. Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol Pharmacol. 1975 Sep;11(5):528–544. [PubMed] [Google Scholar]
  24. Kinlough-Rathbone R. L., Packham M. A., Mustard J. F. The effect of prostaglandin E1 on platelet function in vitro and in vivo. Br J Haematol. 1970 Nov;19(5):559–571. doi: 10.1111/j.1365-2141.1970.tb01639.x. [DOI] [PubMed] [Google Scholar]
  25. Mills D. C., Smith J. B. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3':5'-cyclic monophosphate in platelets. Biochem J. 1971 Jan;121(2):185–196. doi: 10.1042/bj1210185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Moncada S., Bunting S., Mullane K., Thorogood P., Vane J. R., Raz A., Needleman P. Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins. 1977 Apr;13(4):611–618. doi: 10.1016/0090-6980(77)90232-5. [DOI] [PubMed] [Google Scholar]
  27. Moncada S., Gryglewski R. J., Bunting S., Vane J. R. A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins. 1976 Nov;12(5):715–737. doi: 10.1016/0090-6980(76)90048-4. [DOI] [PubMed] [Google Scholar]
  28. Needleman P., Raz A., Ferrendelli J. A., Minkes M. Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1716–1720. doi: 10.1073/pnas.74.4.1716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Nijkamp F. P., Moncada S., White H. L., Vane J. R. Diversion of prostaglandin endoperoxide metabolism by selective inhibition of thromboxane A2 biosynthesis in lung, spleen or platelets. Eur J Pharmacol. 1977 Jul 15;44(2):179–186. doi: 10.1016/0014-2999(77)90104-2. [DOI] [PubMed] [Google Scholar]
  30. Packham M. A., Guccione M. A., Chang P. L., Mustard J. F. Platelet aggregation and release: effects of low concentrations of thrombin or collagen. Am J Physiol. 1973 Jul;225(1):38–47. doi: 10.1152/ajplegacy.1973.225.1.38. [DOI] [PubMed] [Google Scholar]
  31. Roth G. J., Majerus P. W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975 Sep;56(3):624–632. doi: 10.1172/JCI108132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Salzman E. W., Kensler P. C., Levine L. Cyclic 3',5'-adenosine monophosphate in human blood platelets. IV. Regulatory role of cyclic amp in platelet function. Ann N Y Acad Sci. 1972 Oct 27;201:61–71. doi: 10.1111/j.1749-6632.1972.tb16287.x. [DOI] [PubMed] [Google Scholar]
  33. Smith J. B., Silver M. J., Webster G. R. Phospholipase A-1 of human blood platelets. Biochem J. 1973 Mar;131(3):615–618. doi: 10.1042/bj1310615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Smith J. B., Willis A. L. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol. 1971 Jun 23;231(25):235–237. doi: 10.1038/newbio231235a0. [DOI] [PubMed] [Google Scholar]
  35. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  36. Venton D. L., Enke S. E., Le Breton G. C. Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation. J Med Chem. 1979 Jul;22(7):824–830. doi: 10.1021/jm00193a014. [DOI] [PubMed] [Google Scholar]
  37. Verstraete M. Are agents affecting platelet functions clinically useful? Am J Med. 1976 Dec;61(6):897–914. doi: 10.1016/0002-9343(76)90414-9. [DOI] [PubMed] [Google Scholar]
  38. Weiss H. J. Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis. Am Heart J. 1976 Jul;92(1):86–102. doi: 10.1016/s0002-8703(76)80408-5. [DOI] [PubMed] [Google Scholar]
  39. Weksler B. B., Marcus A. J., Jaffe E. A. Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3922–3926. doi: 10.1073/pnas.74.9.3922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Willis A. L. Isolation of a chemical trigger for thrombosis. Prostaglandins. 1974 Jan 10;5(1):1–25. doi: 10.1016/s0090-6980(74)80126-7. [DOI] [PubMed] [Google Scholar]
  41. Willis A. L., Vane F. M., Kuhn D. C., Scott C. G., Petrin M. An endoperoxide aggregator (Lass), formed in platelets in response to thrombotic stimuli: purification, identification and unique biological significance. Prostaglandins. 1974 Dec 25;8(6):453–507. doi: 10.1016/0090-6980(74)90062-8. [DOI] [PubMed] [Google Scholar]
  42. Wolfe S. M., Shulman N. R. Adenyl cyclase activity in human platelets. Biochem Biophys Res Commun. 1969 Apr 29;35(2):265–272. doi: 10.1016/0006-291x(69)90277-0. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES